ArticleImmunologic research2025
The osteoclast blind spot and other unresolved mechanisms in the exosomal theory of tuberculosis-induced osteoporosis.
Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent study by Zhao et al. ( Inflamm Res. 2025) proposed a novel paradigm in which exosomal miR-125b-5p from Mycobacterium tuberculosis-infected macrophages impairs osteoblast function by targeting IGF2, thereby linking pulmonary infection to systemic osteoporosis. While this work provides a valuable mechanistic insight, our letter offers a critical appraisal to contextualize its findings and highlight pivotal unanswered questions. We posit that the proposed pathway, though compelling, requires further validation to establish direct causality in vivo, independent of the well-established role of systemic inflammatory cytokines. Furthermore, the model remains incomplete as it overlooks the potential synergistic impact of the exosomal cargo on osteoclast activation, thereby presenting only a partial view of the bone remodeling unit. Substantive questions regarding the specificity of miR-125b-5p as the sole effector, the biodistribution mechanisms of these exosomes, and their pathogen-specific nature also warrant urgent investigation. Addressing these gaps is not merely academic but is crucial for assessing the true therapeutic potential of targeting this exosomal axis in clinical practice.
Indexed as
Identifiers
41296095What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.